SAN DIEGO– Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer. Dr. Robinson brings 30 years of industry expertise and experience from key strategy roles at large pharma companies, including Merck KGaA, Bayer, and Amgen.
“We are thrilled to welcome Byron to our executive leadership team, bringing his impressive track record of systematically evaluating market opportunities to drive successful clinical strategy,” said David Campbell, Ph.D., President and CEO of Janux. “His insights and strategic experience will make him a critical addition to the team as we continue to leverage our novel TRACTr and TRACIr platforms to advance our broad pipeline of next-generation immunotherapies towards the clinic.”
Prior to joining Janux, Dr. Robinson served as Senior Vice President of Clinical Development Strategy and Innovation at Merck KGaA. In this role, he was responsible for generating strategic insights for internal and external innovation for the generation of the Clinical Oncology Franchise Strategy for all Merck KGaA oncology assets. In addition, he also served as the Senior Vice President Global Program Leader for the avelumab program, where he advanced BAVENCIO® through late-stage development, including eleven registrational Phase 3 trials and more than 240 clinical trials. Prior to Merck KGaA, Dr. Robinson was Vice President, Senior Global Program Head, Oncology (Early & Late) at Bayer, developing several assets, including ALIQOPA® (copanlisib), in the hematology-oncology and solid tumor spaces. Prior to Bayer, he was Global Project Manager on seventeen different assets across multiple therapeutic areas for Amgen Inc. Byron earned his B.Sc. and Ph.D. in organic chemistry from the University of New England, Armidale, Australia and completed his J.D. from Santa Barbara College of Law.
“This is a particularly exciting time to be joining Janux, as the Company identifies areas to maximize the value of its product candidates,” said Dr. Robinson. “With an outstanding leadership team and two compelling platform technologies that together support a broad range of clinical opportunities, Janux is well-positioned to prosecute in areas that represent significant unmet needs. I look forward to helping steer the Company’s next phase of growth.”
